The FDA has qualified its first artificial intelligence tool to help drug developers evaluate fatty liver disease in their ...

PathAI, a global leader in AI-powered pathology, today announced that the U.S. Food and Drug Administration (FDA) has qualified AIM-MASH AI Assist through the Drug Development Tool (DDT) Biomarker ...

The FDA has qualified the first AI-based tool that can be used in clinical trials involving patients with metabolic ...

Dec 8 (Reuters) - The U.S. Food and Drug Administration has qualified the first artificial intelligence tool designed to help ...

MedPage Today brought together three hepatology experts for a virtual roundtable discussion on metabolic ...

A silent health crisis may be developing inside your body without any obvious warning signs. Metabolic dysfunction-associated steatohepatitis (MASH) represents a serious form of fatty liver disease ...

Imagine sitting in a doctor’s office and being told you have “non-alcoholic” liver disease. Before the doctor even finishes explaining what that means, your brain is already doing gymnastics trying to ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. GLP-1 receptor agonist use in diabetes and obesity has ...

A groundbreaking AI tool, AIM-NASH, has received FDA approval to revolutionize liver disease drug trials. This innovative ...

At the Liver Meeting sponsored by the American Association for the Study of Liver Diseases, investigators presented new ...

Former Miami Dolphins quarterback Dan Marino is opening up about his health in the hope that more people will stay on top of their routine exams. The 64-year-old says that one of those annual visits ...

MASH patients exhibit a higher spleen-to-liver stiffness ratio than ALD patients, indicating a presinusoidal component in portal hypertension. The study found that MASH patients have larger spleen ...